Pfizer Pulls Leukemia Treatment

Mylotarg, a Wyeth drug inherited by Pfizer during the megamerger was shrouded with hope and optimism after FDA gave Mylotarg fast-track approval in 2000 to help patients with acute myeloid leukemia -- a devastating form of leukemia that attacks the bone marrow. The original purpose of the accelerate...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical Executive 2010-07, Vol.30 (7), p.19
Main Author: Koroneos, George
Format: Article
Language:English
Subjects:
FDA approval
Leukemia
Pharmaceuticals
R&D
Research & development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mylotarg, a Wyeth drug inherited by Pfizer during the megamerger was shrouded with hope and optimism after FDA gave Mylotarg fast-track approval in 2000 to help patients with acute myeloid leukemia -- a devastating form of leukemia that attacks the bone marrow. The original purpose of the accelerated approval program was to get potentially life saving drugs to people who need them as early as possible. However, as in the case of Mylotarg, there is always the chance that the treatment might not work as planned.
ISSN:0279-6570
2150-735X